Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Lymphoid 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thrombocytopenia 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × romiplostim × Thoracic × Clear all
NCT00413283 2013-10-24

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Amgen

Phase 2 Completed
63 enrolled 15 charts
Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡